Peringkat dalam Saham
#33514
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Kapitalisasi Pasar
$7.16M
Perubahan (1 tahun)
-40.95%
Perdagangan TME Pharma N.V. (ALTME)
Harga ALTME dengan kapitalisasi pasar B
Kapitalisasi pasar dari TME Pharma N.V.(ALTME)
Kapitalisasi Pasar: $7.16M
Per August 2026, TME Pharma N.V. memiliki kapitalisasi pasar sebesar $7.16M. Ini menjadikan TME Pharma N.V. sebagai perusahaan 33514th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar TME Pharma N.V. dari 2016 hingga 2026
ALTME dibandingkan dengan 5 teratas stocks paling populer
| Harga ALTME |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.452T
|
+76,125,253.52%
|
|
|
|
|
$4.490T
|
+62,694,812.90%
|
|
|
|
|
$4.162T
|
+58,120,294.94%
|
|
|
|
|
$3.676T
|
+51,333,292.80%
|
|
|
|
|
$2.833T
|
+39,558,154.52%
|
